Bergmann Anthony 4

What Happened

• Anthony Bergmann, Chief Financial Officer of Capricor Therapeutics, exercised 25,000 option-derived shares at $3.18 per share (cost $79,500) and sold 25,000 common shares in the open market at a weighted average price of $31.70 per share (gross proceeds ≈ $792,540) on May 1, 2026. The filing also reports a disposition of 25,000 derivative shares at $0.00 (reported as a derivative disposition on the Form 4).
• This sequence (exercise + same-day sale) is effectively a cashless exercise: options were converted into shares and an equal number of shares were sold the same day. The sale was executed under a pre-established 10b5-1 trading plan.

Key Details

• Transaction date: 2026-05-01.
• Option exercise: 25,000 shares at $3.18/share (total $79,500).
• Open-market sale: 25,000 shares at weighted avg $31.70/share (range $30.89–$33.19); gross proceeds ≈ $792,540.
• Derivative disposition: 25,000 shares reported disposed at $0.00 (reported on Form 4; typically reflects shares withheld or surrendered in connection with an exercise/settlement).
• Footnotes: F1 — sale pursuant to a 10b5-1 plan adopted Dec 2025; F2 — weighted-average sale price shown (range provided); F3 — shares vest 1/48th monthly beginning Feb 1, 2022.
• Shares owned after the transaction: not specified in the provided details.
• Filing timeliness: Reported on 2026-05-04; filing is within the Form 4 deadline for a May 1 transaction (timely).

Context

• Code meanings: M = option exercise/conversion; S = open-market sale. When an insider exercises options and immediately sells the shares, it is typically a cashless exercise (insider realizes the spread between exercise price and sale price).
• Sales under a 10b5-1 plan are pre-planned transactions and are often routine; they do not, by themselves, indicate the insider’s current view of the company.